A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer

Autor: Nilsson, S., Strang, P., Aksnes, A.K., Franzèn, L., Olivier, P., Pecking, A., Staffurth, J., Vasanthan, S., Andersson, C., Bruland, Ø.S.
Zdroj: In European Journal of Cancer March 2012 48(5):678-686
Databáze: ScienceDirect
Externí odkaz: